Lawsuit Overview - The class action lawsuit against BioAge Labs alleges violations of the Securities Act of 1933, specifically that the IPO offering documents contained materially false and/or misleading statements regarding the safety and expected results of the STRIDES clinical trial [1][3] - The lawsuit is captioned Soto v BioAge Labs, Inc, No 25-cv-00196 (N D Cal) and purchasers or acquirers of BioAge Labs stock pursuant to the IPO have until March 10, 2025 to seek appointment as lead plaintiff [1] BioAge Labs Background - BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases [2] - In its IPO on September 26, 2024, BioAge Labs sold 12 65 million shares at $18 00 per share [2] Allegations and Impact - The lawsuit alleges that on December 6, 2024, BioAge Labs announced discontinuation of the STRIDES Phase 2 study of its investigational drug candidate azelaprag due to liver transaminitis observed in some subjects [4] - Following this announcement, BioAge Labs stock price fell more than 76% and was trading at or around $5 82 per share, significantly below the $18 00 IPO price [4] Lead Plaintiff Process - Under the Private Securities Litigation Reform Act of 1995, any investor who purchased or acquired BioAge Labs stock pursuant to the IPO can seek appointment as lead plaintiff [5] - The lead plaintiff, typically the movant with the greatest financial interest, acts on behalf of all class members and can select a law firm to litigate the case [5] Robbins Geller Law Firm - Robbins Geller Rudman & Dowd LLP is representing investors in this securities fraud case [6] - The firm has recovered $6 6 billion for investors in securities-related class action cases over the last four years, including the largest securities class action recovery ever of $7 2 billion in the Enron case [6]

NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioAge investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all shareholders that purchased stock pursuant and/or traceable to BioAge's registration statement for the initial public offering held on or about September 26 ...

LOS ANGELES, Jan. 10, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ: BIOA) for violations of the federal securities laws.Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ("IPO") conducted on September 26, 2024, are encouraged to contact the firm before March 10, 2025.      If you are a s ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge's initial public offering conducted on September 26, 2024 (the "IPO"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 10, 2025.So what: If you purchased BioAge stock you may be enti ...

SAN FRANCISCO, Jan. 9, 2025 /PRNewswire/ -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and prospects of a key drug candidate before its initial public offering last September.Hagens Berman urges investors who purchased BioAge shares in the company's IPO or on the open market and suffered substantial losses to submit your losses now.Defined Class: Purchasers ...

ATLANTA, Jan. 09, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA). The lawsuit alleges that the Company’s registration statement issued in connection with its IPO was false and/or misleading because Defendants failed to disclose safety concerns related to its lead product candidate, azelaprag. If you bought shares of BioAge on or after September 26, 2024 and you suffered a significant loss on that investment, you ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Investors have until March 10, 2025, to ask the Court to be appointed to lead the case ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=121492&from=4 CLASS PERIOD: This lawsuit is on ...

NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether BioAge and certain of its officers and/ ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) securities on BioAge Labs’ initial public offering (the “IPO”) held on September 26, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the ...